![[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Quantum Immunologics (QI): Agenda 3 4 7 10 12 15 18 11](data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7)
Recommandé
Recommandé
Contenu connexe
Tendances
Tendances (20)
Similaire à Quantum Immunlogics
Similaire à Quantum Immunlogics (20)
Dernier
Dernier (20)
Quantum Immunlogics
- 1. Fighting Cancer With Leading Edge Immunotherapy November 2009
- 10. QI’s Process: Video of OFA / Dendritic Cell Immunotherapy
- 12. Chemotherapy Herceptin QI ImmunoTx Micro Economic Perspective of Treatment Options for Metastatic Breast Cancer Total Cost Patient Side Effects Number of Treatments 4 – 20+ IV - Year long, every week or every 3 weeks 3 injections, monthly intervals $10,000 - $200,000 $70,000 - $100,000 $60,000 Can Be Multiple and Severe Some, and likely to be Moderate Minimal, and likely to be Mild
- 15. Looking Ahead: QI’s Ongoing Research & Development
- 19. Jul Oct Jan Sep Dec Mar Apr Aug Nov Feb 2008 2009 Opened TN Lab to conduct further cancer research and immunotherapy product development Filed two provisional patent applications involving cutting-edge cancer immunotherapies and diagnostics Took control of management and operations of the AL Lab to oversee and conduct Phase I/II Trial Secured Exclusive Worldwide License Agreement for all products/patents developed by SAMSF related to OFA Begin Phase I/II Trials of immunotherapy for Stage IV Breast Cancer Patients QI’s Historical Milestone Dates May Jun QI receives FDA authorization for Phase I/II Clinical Trial for Stage IV Breast Cancer Patients Oct QI presented at the Rodman & Renshaw Global Investor Conference
- 22. QI’s Capitalization: Past Capital Raising Initiatives Capital Raising Tranche $ per share # Warrants $ Amount Invested # Shares Issued # Warrants Issued Imputed Price per Share Tranche 1 $10 3 $ 924,100 92,410 277,230 $ 3.57 Tranche 2 $10 2 $ 2,169,712 216,971 433,942 $ 4.55 Tranche 3 $10 1 $ 1,104,720 110,472 110,472 $ 6.25 Mentor Capital * *note receivable $12 na $ 2,244,000 187,000 na $ 12.00 TOTAL: $ 6,442,532 606,853 821,644 Non-cash Shares Founders/Directors/CEO 237,757 VRI / Venturific 82,172 Total Shares Outstanding 926,782
- 23. QI Summary Capitalization Table (as of 9-30-09) Current Shares Current Warrants Total # Outstanding 926,782 821,644 QI Equity Capitalization $ 11,121,384 Round 1 Shares Total $ Amount $ 5,000,000 Share Price $ 12 # Shares 416,666 % of QI Outstanding 31.0% Post Round 1 Shares Total # Outstanding 1,343,448 QI Equity Capitalization $ 16,121,376
- 24. Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec Dec Nov Oct Phase I/II Trial Phase II b/ III Trial R&D Corp. 2009 2010 QI: Estimated Timeline Through 2010 Financing Take on FTEs Round 1 - $5mm Continue to Follow Up FDA Application/Planning Process Round 2 – IPO/Rev Merge Shell + SPO/JV/Acquisition
- 27. Fighting Cancer With Leading Edge Immunotherapy November 2009
Notes de l'éditeur
- The OFA antigen is found not only on breast cancer, but on many other cancers including lung, liver and renal. In fact, OFA has been found on every mammalian cancer that has been studied according to a paper published in the Journal of Modern Aspects of Immunobiology
- Important to recognize that it was the FDA that kicked QI into a Phase II trial. The initial application was only for a Phase I trail, but the FDA “suggested” that QI go ahead and do a Phase II trial as well.
- And recall that QI has the exclusive license for other countries beside just the US. So when you look at the unmet medical need worldwide…it’s huge.
- If QI’s immuno-therapy approach for Stage IV breast cancer patients, it is logical to start to utilize the QI immuno-therapy approach for all breast cancer patients, given the much more favorable side effects profile. And the market for all breast cancer patients is BEYOND HUGE.
- QI’s R&D staff continue to work on finding even better approaches to combating cancer.
- Anti bodies stick to the peptides found on OFA Given that OFA appears to be a universal cancer marker, these antibodies can be “tagged” with chemical or radiological markers to detect the presence of OFA/cancer in tissue and blood.
- QI has accomplished much in a short amount of time.
- One of the interesting aspects of QI is their use of Independent Contractors. Most of the above folks are independent contractors who have been working for QI stock. QI recognizes that as QI evolves, QI knows that many of these independent contractors will have to come on board as traditional, full time employees. But this approach has allowed QI to conserve capital.